Cabaletta Bio shares are trading lower. The company announced initial clinical data from each of the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials.
Portfolio Pulse from Benzinga Newsdesk
Cabaletta Bio shares are trading lower following the announcement of initial clinical data from the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials.
June 14, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cabaletta Bio shares are trading lower after the company announced initial clinical data from the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials.
The announcement of initial clinical data from early-stage trials often leads to stock price volatility. In this case, the data appears to have been received negatively by the market, causing a drop in share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100